ScripOne key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up
In VivoA key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of